Cargando…

Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences

Diabetes mellitus (DM), a group of diseases characterized by defective glucose metabolism, is the most widespread metabolic disorder affecting over 400 million adults worldwide. This pathological condition has been implicated in the pathogenesis of a number of central encephalopathies and peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sergi, Domenico, Renaud, Justine, Simola, Nicola, Martinoli, Maria-Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856011/ https://www.ncbi.nlm.nih.gov/pubmed/31787891 http://dx.doi.org/10.3389/fnagi.2019.00302

Ejemplares similares

The sweet road to Parkinson’s disease
por: Renaud, Justine, et al.
Publicado: (2019)

Anti-Apoptotic and Anti-Inflammatory Role of Trans ε-Viniferin in a Neuron–Glia Co-Culture Cellular Model of Parkinson’s Disease
por: Sergi, Domenico, et al.
Publicado: (2021)

Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases
por: Renaud, Justine, et al.
Publicado: (2019)

Dysfunction of Cellular Proteostasis in Parkinson’s Disease
por: Lehtonen, Šárka, et al.
Publicado: (2019)

Oleuropein Prevents Neuronal Death, Mitigates Mitochondrial Superoxide Production and Modulates Autophagy in a Dopaminergic Cellular Model
por: Achour, Imène, et al.
Publicado: (2016)

Resveratrol Protects DAergic PC12 Cells from High Glucose-Induced Oxidative Stress and Apoptosis: Effect on p53 and GRP75 Localization
por: Renaud, Justine, et al.
Publicado: (2013)

Gender Differences in Neurodegeneration, Neuroinflammation and Na(+)-Ca(2+) Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease
por: Costa, Giulia, et al.
Publicado: (2020)

Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease
por: Zeng, Xian-Si, et al.
Publicado: (2018)

Quercetin and Sesamin Protect Dopaminergic Cells from MPP(+)-Induced Neuroinflammation in a Microglial (N9)-Neuronal (PC12) Coculture System
por: Bournival, Julie, et al.
Publicado: (2012)

The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson’s Disease
por: Ceravolo, Roberto, et al.
Publicado: (2012)

Role of movement in long-term basal ganglia changes: implications for abnormal motor responses
por: Simola, Nicola, et al.
Publicado: (2013)

Evidence for Peripheral Immune Activation in Parkinson’s Disease
por: Chen, Xueping, et al.
Publicado: (2021)

A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease
por: Morelli, Micaela, et al.
Publicado: (2012)

RISC in PD: the impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis
por: Heman-Ackah, Sabrina M., et al.
Publicado: (2013)

Reduced Cytosolic Calcium as an Early Decisive Cellular State in Parkinson’s Disease and Synucleinopathies
por: Betzer, Cristine, et al.
Publicado: (2018)

Parkinson’s Disease: Overview of Transcription Factor Regulation, Genetics, and Cellular and Animal Models
por: Xia, Ninuo, et al.
Publicado: (2022)

Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinson’s Disease
por: Lualdi, Marta, et al.
Publicado: (2019)

Centrality of Early Synaptopathy in Parkinson’s Disease
por: Imbriani, Paola, et al.
Publicado: (2018)

Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
por: Plotegher, Nicoletta, et al.
Publicado: (2019)

Epidemiological Evidence for an Immune Component of Parkinson’s Disease
por: Gonzalez-Latapi, Paulina, et al.
Publicado: (2022)

Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
por: Emamzadeh, Fatemeh N., et al.
Publicado: (2018)

Hypernasality associated with basal ganglia dysfunction: evidence from Parkinson’s disease and Huntington’s disease
por: Novotný, Michal, et al.
Publicado: (2016)

Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles
por: Labadorf, Adam, et al.
Publicado: (2018)

Neuropsychology of the parietal lobe: Luria’s and contemporary conceptions
por: Souza-Couto, Dyecika, et al.
Publicado: (2023)

Neuroprotective and Neurorestorative Effects of Holothuria scabra Extract in the MPTP/MPP(+)-Induced Mouse and Cellular Models of Parkinson’s Disease
por: Noonong, Kunwadee, et al.
Publicado: (2020)

Cellular Senescence in Traumatic Brain Injury: Evidence and Perspectives
por: Schwab, Nicole, et al.
Publicado: (2021)

Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences
por: Costa, Giulia, et al.
Publicado: (2021)

TARDBP mutations in a cohort of Italian patients with Parkinson’s disease and atypical parkinsonisms
por: Tiloca, Cinzia, et al.
Publicado: (2022)

How Cognition and Motivation “Freeze” the Motor Behavior in Parkinson’s Disease
por: Ortelli, Paola, et al.
Publicado: (2019)

Parkinson’s Is Time on Your Side? Evidence for Difficulties with Sensorimotor Synchronization
por: Bieńkiewicz, Marta M. N., et al.
Publicado: (2015)

Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson’s disease
por: Turski, Paweł, et al.
Publicado: (2022)

Complementary and Alternative Medicine for Idiopathic Parkinson’s Disease: An Evidence-Based Clinical Practice Guideline
por: Cho, Ki-Ho, et al.
Publicado: (2018)

Practice of Contemporary Dance Improves Cognitive Flexibility in Aging
por: Coubard, Olivier A., et al.
Publicado: (2011)

The Emergent Engram: A Historical Legacy and Contemporary Discovery
por: Devan, Bryan D., et al.
Publicado: (2018)

Quantitative Analysis of Bradykinesia and Rigidity in Parkinson’s Disease
por: di Biase, Lazzaro, et al.
Publicado: (2018)

Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
por: Avenali, Micol, et al.
Publicado: (2020)

Dopamine Replacement Therapy, Learning and Reward Prediction in Parkinson’s Disease: Implications for Rehabilitation
por: Ferrazzoli, Davide, et al.
Publicado: (2016)

Action Fluency in Parkinson’s Disease: A Mini-Review and Viewpoint
por: Gianelli, Claudia, et al.
Publicado: (2021)

Therapies for Parkinson’s disease and the gut microbiome: evidence for bidirectional connection
por: Hey, Grace, et al.
Publicado: (2023)

Adenosine A(1)-A(2A) Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9m116aeve121g16fffokkktcgr